Circulating endothelial cells and progenitors as prognosis factors during auto-immune thrombotic thrombocytopenic purpura: results of a prospective multicenter french study

被引：0
|
作者：
Widemann, A. [1 ]
Pasero, C. [2 ]
Arnaud, L. [2 ]
Poullin, P. [3 ]
Loundou, A. [4 ]
Choukroun, G. [5 ]
Sanderson, F. [6 ]
Lacroix, R. [2 ,7 ]
Sabatier, F. [7 ,8 ]
Coppo, P. [9 ]
Dignat-George, F. [2 ,7 ]
Kaplanski, G. [7 ,10 ]
机构：
[1] Aix Marseille Univ, Vasc Res Ctr Marseille, INSERM, UMR 1076, Marseille, France
[2] APHM, Serv Hematol, CHU Concept, Marseille, France
[3] APHM, Serv Hemapherese & dAutotransfus, CHU Concept, Marseille, France
[4] APHM, Unit Aide Methodol Rech Clin, Marseille, France
[5] CHU Amiens, Dept Nephrol, Amiens, France
[6] Hop Archet, Serv Med Interne, Nice, France
[7] Aix Marseille Univ, Vasc Res Ctr Marseille, INSERM, UMR 1076, Marseille, France
[8] APHM, CHU Concept, INSERM, Lab Culture & Therapie Cellulaire,CIC BT510, Marseille, France
[9] Hop St Antoine, APHP, Dept Hematol, Ctr Reference Microangiopathies Thrombot, Marseille, France
[10] APHM, CHU Concept, Serv Med Interne, Marseille, France
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2014年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
VB10
引用
收藏
页码：87 / 87
页数：1
相关论文
共 8 条
  • [1] Circulating endothelial cells and progenitors as prognostic factors during autoimmune thrombotic thrombocytopenic purpura: results of a prospective multicenter French study
    Widemann, A.
    Pasero, C.
    Arnaud, L.
    Poullin, P.
    Loundou, A. D.
    Choukroun, G.
    Sanderson, F.
    Lacroix, R.
    Sabatier, F.
    Coppo, P.
    Dignat-George, F.
    Kaplanski, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (10) : 1601 - 1609
  • [2] Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura
    Boothby, Aaron B.
    Evans, Michael D.
    Yang, Shangbin
    Sukumar, Senthil
    Scott, James G.
    Terrell, Deirdra R.
    Cataland, Spero
    Mazepa, Marshall
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (03)
  • [3] Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: Results of a multicenter prospective phase 2 study.
    Godeau, Bertrand
    Fain, Olivier
    Porcher, Raphael
    Lefrere, Francois
    Fenaux, Pierre
    Cheze, Stephane
    Vekhoff, Anne
    Chauveheid, Marie-Paule
    Stirnemann, Jerome
    Galicier, Lionel
    Bourgeois, Emmanuelle
    Haiat, Stephanie
    Varet, Bruno
    Leporrier, Michel
    Papo, Thomas
    Michel, Marc
    Bierling, Philippe
    BLOOD, 2006, 108 (11) : 145A - 145A
  • [4] Preliminary findings from the prospective multicenter surveillance, epidemiology and risk factors for thrombotic thrombocytopenic purpura (SERF-TTP) study.
    Zakarija, A
    Bandarenko, N
    Pandey, DK
    Kwaan, H
    McCaffrey, K
    Finley, D
    Carson, K
    Yarnold, P
    Bennett, CL
    BLOOD, 2004, 104 (11) : 244A - 244A
  • [5] Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
    Godeau, Bertrand
    Porcher, Raphael
    Fain, Olivier
    Lefrere, Francois
    Fenaux, Pierre
    Cheze, Stephane
    Vekhoff, Anne
    Chauveheid, Marie-Paule
    Stirnemann, Jerome
    Galicier, Lionel
    Bourgeois, Emmanuelle
    Haiat, Stephanie
    Varet, Bruno
    Leporrier, Michel
    Papo, Thomas
    Khellaf, Mehdi
    Michel, Marc
    Bierling, Philippe
    BLOOD, 2008, 112 (04) : 999 - 1004
  • [6] Serum pepsinogens can help to discriminate between H. pylori -induced and auto-immune atrophic gastritis: Results from a prospective multicenter study
    Chapelle, Nicolas
    Martin, Jerome
    Osmola, Malgorzata
    Hemont, Caroline
    Leroy, Maxime
    Vibet, Marie -Anne
    Tougeron, David
    Moussata, Driffa
    Lamarque, Dominique
    Bigot-Corbel, Edith
    Masson, Damien
    Blin, Justine
    Josien, Regis
    Mosnier, Jean-Francois
    Matysiak-Budnik, Tamara
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (10) : 1345 - 1351
  • [7] First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies
    Froissart, Antoine
    Buffet, Marc
    Veyradier, Agnes
    Poullin, Pascale
    Provot, Francois
    Malot, Sandrine
    Schwarzinger, Michael
    Galicier, Lionel
    Vanhille, Philippe
    Vernant, Jean-Paul
    Bordessoule, Dominique
    Guidet, Bertrand
    Azoulay, Elie
    Rondeau, Eric
    Mira, Jean-Paul
    Wynckel, Alain
    Clabault, Karine
    Choukroun, Gabriel
    Presne, Claire
    Pourrat, Jacques
    Hamidou, Mohamed
    Gimeno, Linda
    Coppo, Paul
    BLOOD, 2009, 114 (22) : 366 - 367
  • [8] Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study
    Pierga, J-Y
    Tredant, O.
    Chevrier, M.
    Dubot, C.
    Lorgis, V.
    Romieu, G.
    Goncalves, A.
    Debled, M.
    Levy, C.
    Ferrero, J-M
    Jouannaud, C.
    Luporsi, E.
    Mouret-Reynier, M-A
    Dalenc, F.
    Berger, F.
    Lemonnier, J.
    Proudhon, C.
    Bidard, F-C
    CANCER RESEARCH, 2017, 77
1